0.39Open0.55Pre Close184 Volume38.91K Open Interest3.00Strike Price8.04KTurnover56.57%IV-0.29%PremiumJan 17, 2025Expiry Date0.41Intrinsic Value100Multiplier10DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9233Delta0.4509Gamma8.02Leverage Ratio-0.0026Theta0.0007Rho7.41Eff Leverage0.0008Vega
Revance Therapeutics Stock Discussion
Dow Jones· 1 min ago
Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash
Monday, 6th January at 9:00 am
Compelling Cash Proposal Provides 16% Premium Over Revance's Amended and Restated Agreement with Crown Laboratories
GENEVA, Jan. 6, 2025 /PRNewswire/ -- Teoxane SA today announced that on January 6, 2025, it submitted a proposal to the Board of Directors of Revance Therapeutics, Inc. (NASDAQ: RVNC) to acquire Revance for $3.60 per s...
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
No comment yet